Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New ...
Dupixent 300 mg weekly showed significant histological disease remission and improvement in symptoms of the disease compared to placebo Improvements were sustained for up to one year in patients aged 12 years and older with eosinophilic esophagitis (EoE) …